Femasys Secures Key Patents for FemBloc Polymer Technology
Event summary
- Femasys Inc. secured new patents in the U.S. and seven other countries for FemBloc's blended polymer technology.
- The patents (US Patent No. 12606719, JP Patent Nos. 7379157/7594647, KR Patent No. 10-2713236, etc.) complement existing delivery system patents.
- FemBloc is approved in Europe and other select international markets but remains investigational in the U.S.
- The company is conducting a pivotal trial (NCT05977751) for U.S. FDA approval of FemBloc.
The big picture
Femasys' new polymer patents strengthen its intellectual property position as it seeks to disrupt the $1.5 billion global female sterilization market with a non-surgical alternative. The move comes amid growing demand for less invasive reproductive health solutions, positioning Femasys to capture share in both developed and emerging markets. Success hinges on securing U.S. approval while maintaining international commercial momentum.
What we're watching
- Regulatory Pathway
- Whether Femasys can successfully navigate the U.S. FDA approval process for FemBloc through its ongoing pivotal trial.
- Market Expansion
- The pace at which Femasys can commercialize FemBloc in newly patented markets beyond Europe.
- Competitive Positioning
- How the expanded patent portfolio will affect Femasys' competitive advantage in non-surgical permanent birth control.